Tariffs on Cheap Drugs: Why a Tariff Could Turn into a Pharmacy Bill

You're standing at the pharmacy counter, the pharmacist clicks away on the system for a moment, and then comes the sentence no one likes to hear: the same medication is either unavailable or more expensive. This isn't luxury goods where you might decide that a new phone can wait a year. With antibiotics, blood pressure, diabetes, or cholesterol medications, there's little room for heroics.

This is where today's big topic in the financial world begins: the potential U.S. tariff on imported generic drugs. Several financial media outlets today highlight the warning from Richard Saynor, head of the Swiss pharmaceutical group Sandoz, that sharp tariffs would likely not be absorbed solely within the margins of generic manufacturers. They would either raise prices or some supplies to the U.S. would cease to make economic sense.

And this is more important than it seems at first glance. Generics are not a market niche. They are cheap copies of drugs after patent expiration and form the backbone of everyday medicine. When politics mentions tariffs, we often think of cars, steel, or solar panels. But with drugs, the final recipient is more sensitive: the patient, the insurance company, hospitals, and state budgets.

Why Generics Hurt More Than Premium Drugs

With an expensive patented drug, the price is often high, the margins more robust, and the company has some negotiating power. With generics, the logic is different. They are manufactured by multiple companies, competing mainly on price, and buyers push costs down. The result is that patients and healthcare systems receive cheap drugs, but manufacturers operate in a thinner economic space.

In the U.S., generics account for approximately nine out of ten prescriptions issued, but only a smaller part of total drug spending, often cited as around one-fifth or less. This beautifully illustrates their role: huge volume, low unit price.

However, a tariff is a percentage surcharge on imports. If the business model is based on low price and high volume, every additional percentage of costs is noticeable. For a drug with a monthly price in the range of a few dollars, the tariff might seem small in absolute terms. But for the manufacturer, distributor, and hospital procurement, it can determine whether the product is even worth keeping on the market.

That's the point of the statement that the tariff is ultimately paid by the patient. Economically more accurate would be to say: the cost has to be absorbed somewhere. Part can be borne by the manufacturer, part by the distributor, part by the pharmacy, part by the insurance company, and part by the patient. But if there's little margin in the chain, another possibility arises: the manufacturer may prefer to reduce supplies or exit unprofitable items.

What the Journey of a Single Tablet Looks Like

Imagine an ordinary generic drug. The active ingredient might originate in India or China, the tablet could be pressed elsewhere, packaging takes place in another country, and the final product travels through wholesalers to American pharmacies or hospitals. This is not an exception but the norm of the globalized pharmaceutical industry.

The U.S. is the largest and most profitable pharmaceutical market in the world, but it is significantly dependent on imports for cheap generics. India has long been a key supplier of generic drugs for the American market; some estimates speak of a share of around 40% of generics by volume. China, on the other hand, has a strong position in some raw materials and active pharmaceutical ingredients.

The political rationale behind the tariff is understandable: to move part of the production home, reduce dependence on foreign countries, and strengthen industrial security. The problem is time. A drug factory is not a warehouse of T-shirts. It requires approval, process validation, quality control, inspections, and a stable supply chain. Moving production can take years, not quarters.

So if the tariff comes quickly but domestic capacity develops slowly, the market falls into a gap. And in that gap, two things can appear: higher prices and shortages.

Data: Where the System is Already Strained

The American drug market has been dealing with shortages for several years. It's not just an inconvenience like one product being temporarily unavailable. Shortages have affected, for example, chemotherapy drugs, injectable antibiotics, or drugs used in hospitals. Records of drug shortages in the U.S. in recent years have repeatedly shown hundreds of active shortages; in 2024, the number of active shortages, according to American professional overviews, was at historically high levels, numbering over 300 items.

The reasons are recurring: low prices, a small number of manufacturers, quality issues in production, raw material shortages, logistics, and sometimes simply the fact that certain older drugs are not attractive to manufacturers. The generic market can be paradoxical. The cheaper the drug, the fewer economic players are motivated to stay. And the fewer players, the greater the risk that a disruption in one factory will upset the entire supply.

A tariff enters such a system as another cost shock. It's not the same as a coffee price increase in a café where the customer switches to a competitor or opts for tea. With drugs, substitution is often not simple. The drug must have the same active ingredient, dose, form, approval, and availability. In hospitals, purchasing contracts and inventories also play a decisive role.

From the perspective of expected value, the comparison is interesting: a tariff may short-term improve the negotiating position of domestic production and politically demonstrate toughness against imports. But if it increases the likelihood of shortages or rising patient co-payments, part of the costs will return elsewhere — through insurance companies, hospitals, reduced access to care, and pressure on public programs.

Who Might Be Under Pressure and Who Might Relatively Gain

For an investor, the most important thing is not the political headline but the question of cost transfer. Who has pricing power? Who has production in the U.S.? Who sells commodity generics with low margins? Who, on the other hand, is a supplier of specialized drugs with stronger negotiating positions?

The most vulnerable may be companies with a high share of cheap generics imported into the U.S., weaker balance sheets, and little room for price increases. If their customers consist of large buyers, hospital networks, or distribution alliances, it may not be easy to simply pass the tariff into the price.

Relatively more resilient may be companies with diversified production, a larger share of local American production, higher margins, or a portfolio of specialized drugs. But that doesn't automatically mean victory. Production relocation, price regulation, political pressure, and reputational risk can affect the entire sector.

The impact on distributors and pharmacy chains is also interesting. They often operate with large volumes and low margins. If generic prices rise, purchasing conditions, inventories, and negotiations with insurance companies may change. The patient at the checkout will only see the final co-payment, but behind it is a complex game of contracts.

Market Psychology: Why Investors Often React Poorly

When the word tariff appears, the market tends to look for quick winners and losers. Domestic production up, importers down. But pharmaceuticals are slower and more regulated than ordinary industries. A quick reaction can overlook that some domestic capacities are not ready, some companies have long-term contracts, and some costs will manifest with a delay.

The second trap is confusing revenue with business quality. A company may sell huge volumes of drugs, but if the margin is low and debt is high, an additional cost hurts more than for a smaller company with a better product mix. With generics, the old investor rule applies: volume alone is not a moat. A moat arises from regulation, quality, supply reliability, distribution position, and the ability to maintain reasonable capital returns.

The third trap is political timing. An investor reads a headline today, but the law, exceptions, transition periods, and retaliatory measures may come later — or in a completely different form. Therefore, it makes more sense to work with scenarios than with one dramatic forecast.

Practical Framework: How to Analyze the Topic in 20 Minutes

Instead of asking whether a tariff is good or bad, it helps to ask four specific questions.

1. What is the Exposure to the USA

For a pharmaceutical company, look at how much revenue it generates in the United States. The U.S. is a price-attractive market but also very politically visible. If a company has a large portion of its income from American generics, the tariff topic is more significant for it than for a global company with a smaller American share.

2. Where is Production and Where Do Active Ingredients Come From

It's not enough to know where the company is headquartered. A Swiss, Israeli, or American company may manufacture part of its portfolio in India, Europe, China, and the USA. Watch for mentions of manufacturing plants, supply risks, and investments in local production.

3. What is the Margin and Debt

In a low-margin business, a tariff is like a pebble in a marathon runner's shoe. Small by itself, but after ten kilometers, it can be decisive. Gross margin, operating margin, free cash flow, and debt maturities indicate whether the company can handle a cost shock without dramatic compromises.

4. Is the Product a Commodity or a Specialty

Generic paracetamol and a complex injectable drug for hospitals are not economically the same worlds. The more complex the production, the fewer competitors, but also higher quality requirements. In specialized generics and biosimilars, the price dynamics may differ from completely common tablets.

In QMA: for similar topics, it makes sense to look at the sector through a combination of financial strength, margins, debt, and sector classification; in the top selection, companies can be filtered by quality and stability, not just by who was helped by the headline — open in QMA.

Small Domestic Stress Test of the Portfolio

If an investor has pharmaceutical stocks, healthcare ETFs, or suppliers linked to drugs in their portfolio, they can create a simple scenario.

First scenario: a tariff appears but is mild or with exceptions for key drugs. The impact on prices and margins may be limited, but companies will start talking more about production relocation and inventories.

Second scenario: the tariff is significant and widespread. Then the risk of pressure on generic importers, price negotiations, and possible shortages in the least profitable items increases. The market would likely differentiate more between companies with local production and those dependent on imports.

Third scenario: the political threat remains a bargaining chip. Even then, the topic won't disappear. The pandemic has already shown that healthcare supply chains are strategic infrastructure. Governments will continue to address how much production they want at home and how many cheap drugs they are willing to import.

For the average person, the practical impact is simpler than an investor's table: drug availability may not be a given. For chronic medications, it's reasonable to know alternative names of active ingredients, communicate with a doctor in case of a shortage, and not rely on the market to always smoothly replenish stocks within a week. This isn't panic, but rather financial and health hygiene.

What to Take Away

1. Monitor not only revenue growth in pharmaceutical companies but mainly margins, debt, and dependence on the American market. In generics, a small cost shock can change the product's economics.

1. Distinguish between commodity generics, specialized generics, and patented drugs. One word in pharmacy hides several very different business models.

1. Work with scenarios for political tariffs. Important are exceptions, transition periods, the list of affected products, and the ability of companies to relocate production.

1. From a household perspective, it makes sense to know the active ingredient and alternatives for chronic medications that a doctor or pharmacist can offer in case of a shortage. The best response to a fragile supply chain is not panic but preparedness.

---

Sources and Further Reading

This topic was followed by several financial media today. Factual basis and links for further reading:

• CNBC Markets
• Google News · Tariffs

*🤖 Original text QMA Brain — we summarize and supplement the topic in our own words, we do not quote or take text from sources.